Product news

Vinorelbine Injection, USP

Parenta Pharmaceuticals (West Columbia, SC), the US subsidiary of Austrian-based Ebewe Pharma, recently launched Vinorelbine Injection, USP. The product is the generic equivalent of GlaxoSmithKline's Navelbine. Vinorelbine Injection, USP is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non?small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, the product is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, the product is indicated in combination with cisplatin. Vinorelbine Injection, USP is AP-rated, bar-coded, and latex-free and is supplied in 10-mg/mL and 50-mg/5 mL (10-mg/mL) single-dose vials. For more information, visit www.parentarx.com, or call 800-898-9948.

EPS Oral Dispensers

EPS Inc (Ivyland, PA) recently introduced EPS Oral Dispensers. The dispensers contain an innovative One-Piece Plunger construction that eliminates rubber grommets and silicone coating, facilitating an easy sliding of the plunger through the barrel. The dispensers are latex-free and contain graduations in both milliliters and fractionated teaspoon measurements. The EPS Oral Dispensers have a unique tip design, which makes for easier oral and topical dispensing applications. The tip design prohibits acceptance of hypodermic needles, and the low-capacity tip reservoir reduces residual content and ensures maximum delivery of medication. The dispensers can be capped with either Standard Tip Caps or Wagon Wheel stand design. The Wagon Wheel cap provides a solid base for standing dispensers on a countertop where they can be easily handled when administering medication. The product is available in 1-, 3-, 5-, and 10-mL sizes in either clear or ultraviolet-inhibitant amber. For more information, visit www.medidose.com, or call 800-523-8966.

Ketorolac Tromethamine Injection, USP

American Regent Inc (Shirley, NY) recently launched Ketorolac Tromethamine Injection, USP. The product is indicated for the short-term management (<5 days) of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous (IV) or intramuscular (IM) dosing of ketorolac tromethamine. The product, which is AP-rated and latexfree, is available in 15 mg/1 mL and 30 mg/1 mL for IV/IM use, and 60 mg/2 mL for IM use only. For more information, visit www.americanregent.com, or call 800-645-1706.

Lexiscan (regadenoson) Injection

CV Therapeutics Inc (Palo Alto, CA)and Astellas Pharma US Inc (Deerfield,IL) recently received FDA approval forLexiscan Injection, an A_2A adenosinereceptor agonist. The product is a pharmacologicstress agent indicated forradionuclide myocardial perfusion imaging(MPI) in patients unable to undergoadequate exercise stress. The recommendeddose of Lexiscan Injection is 5mL (0.4 mg regadenoson) by rapid intravenousinjection, followed immediatelyby saline flush and radiopharmaceutical.Clinicians should administer LexiscanInjection as a rapid (approximately 10seconds) injection into a peripheral veinusing a 22-gauge-or-larger catheter orneedle. Administer a 5-mL saline flushimmediately after the injection of theproduct. Administer the radionuclideMPI agent 10 to 20 seconds after thesaline flush. The radionuclide may beinjected directly into the same catheteras Lexiscan Injection. The productis supplied as a single-use vial injectionsolution containing regadenoson0.4 mg/5 mL and a single-use prefilledsyringe injection solution containingregadenoson 0.4 mg/5 mL. For moreinformation, visit www.lexiscan.com, orcall 800-888-7704.

Find it Online

For more Hospital Product News, visit www.PharmacyTimes.com/HospitalProducts